Amyloid beta plaques Inhibitors
1 drugsAbout Amyloid beta plaques
Amyloid beta plaques are extracellular deposits primarily composed of Amyloid beta (Aβ) peptides, formed through the cleavage of the amyloid precursor protein (APP). These plaques are a hallmark of Alzheimer's disease and a critical target in central nervous system (CNS) drug development. Their presence is strongly correlated with neuronal dysfunction and cognitive decline.
Targeting Amyloid beta plaques is motivated by their strong association with Alzheimer's. Currently, there is no genetic evidence directly linking this target to disease. Developing therapies that modulate Aβ plaque formation or clearance could offer a promising avenue for treating this neurodegenerative disease.
The target has one FDA-approved diagnostic drug, AMYVID, a small molecule used for detecting plaques. AVID Radiopharmaceuticals Inc. is the sole company with an approved drug for this target, which is indicated for CNS disorders.
Top Amyloid beta plaques Drugs
AVID Radiopharmaceuticals Inc. is the only company with an approved drug targeting Amyloid beta plaques.
The market's low competition presents an opportunity for new entrants with innovative therapeutic approaches.
Amyloid beta plaques Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Amyloid beta plaques, using small molecule modality.
Exploring alternative modalities like antibodies or gene therapies could offer a competitive advantage.
Amyloid beta plaques Clinical Trials 6 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Amyloid beta plaques. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 1 | 0 | 1 | 100% |
| Phase 2 | 2 | 1 | 0 | 1 | 100% |
| Phase 3 | 1 | 1 | 0 | 0 | 100% |
| Phase 4 | 1 | 0 | 1 | 0 | 0% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Amyloid beta plaques Drug Approval Timeline (2012 - 2012)
The first and only drug, AMYVID, was approved in 2012.
The stagnant approval timeline indicates a potential saturation or challenges in developing effective plaque-targeting therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 6 (0 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Amyloid beta plaques. A trial counts if an approved drug acting on Amyloid beta plaques is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.